Status:
COMPLETED
Real-world Study of UTD1 in Chinese Advanced Breast Cancer
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.
Eligibility Criteria
Inclusion
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Plan to receive or has received UTD1 monotherapy or UTD1 based therapy
- Available medical history.
Exclusion
- Incomplete medical history.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05386511
Start Date
April 1 2022
End Date
February 1 2024
Last Update
February 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032